menu
    • menu
    [{"orgOrder":0,"company":"GentiBio","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","amount":"$157.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series A Financing","leadProduct":"Engineered Regulatory T Cell Therapy","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"GentiBio","amount2":0.16,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.16,"dosageForm":"","sponsorNew":"GentiBio \/ Matrix Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"GentiBio \/ Matrix Capital Management"},{"orgOrder":0,"company":"GentiBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"Undisclosed","newsHeadline":"GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Collaboration","leadProduct":"Egineered Treg Cell Therapy","moa":"Treg Cell","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Discovery Platform","graph3":"GentiBio","amount2":1.8999999999999999,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Gastroenterology","productSubType":"","amount2New":1.8999999999999999,"dosageForm":"","sponsorNew":"GentiBio \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"GentiBio \/ Bristol Myers Squibb"}]

    Find Clinical Drug Pipeline Developments & Deals by GentiBio

    Menu

    GentiBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GentiBio

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            GentiBio

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Egineered Treg Cell Therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,900.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammato...

                            Details : GentiBio will apply its engineered regulatory T cell platform in a deal with BMS to develop new engineered Treg therapies to treat inflammatory bowel diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 10, 2022

                            Lead Product(s) : Egineered Treg Cell Therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,900.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GentiBio

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed

                            GentiBio

                            U.S.A arrow
                            FNCE 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Engineered Regulatory T Cell Therapy

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Matrix Capital Management

                            Deal Size : $157.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therape...

                            Details : Funding will advance novel pipeline of best-in-class engineered regulatory T cell therapies to durably restore immune tolerance and treat autoimmune, alloimmune, autoinflammatory, and allergic diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            August 11, 2021

                            Lead Product(s) : Engineered Regulatory T Cell Therapy

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Matrix Capital Management

                            Deal Size : $157.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth